Best Oncotarget Podcasts (2024)

1
Nanobody Inhibits Metastasis of Breast Tumor Cells to Lung in Mice 2:53

2h ago2:53

2:53

BUFFALO, NY- August 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on August 14, 2024, entitled, “A nanobody against the V-ATPase c subunit inhibits metastasis of 4T1-12B breast tumor cells to lung in mice.”The vacuolar H+-ATPase (V-ATPase) is an ATP-dependent proton pump that functions to control the pH of intracellular …

1
Response of BRAF-Mutated Spindle Cell Sarcoma to BRAF/MEK Inhibitors 2:48

6h ago2:48

2:48

BUFFALO, NY- August 14, 2024 – A new #casereport was #published in Oncotarget's Volume 15 on July 17, 2024, entitled, “Rapid but nondurable response of a BRAF exon 15 double-mutated spindle cell sarcoma to a combination of BRAF and MEK inhibitors.”As noted in the introduction of the Abstract, the BRAF V600E substitution predicts a cancer's sensitiv…

1
New Directions in Targeting the Multifaceted BRAF in Cancer 2:28

19h ago2:28

2:28

BUFFALO, NY- August 12, 2024 – A new research perspective was published in Oncotarget's Volume 15 on July 16, 2024, entitled, “Targeting the multifaceted BRAF in cancer: New directions.”In cancer patients, BRAF-targeting precision therapeutics are effective against Class I BRAF alterations (p.V600 hotspot mutations) in tumors such as melanoma, thyr…

1
Combining Regorafenib and TAS102 to Target Gastrointestinal Cancers and Overcome Cancer Stemness 4:01

4d ago4:01

4:01

In this research paper, researchers demonstrate a promising new treatment option for refractory metastatic gastrointestinal cancers using a combination of two FDA-approved drugs.Researchers Jun Zhang, Lanlan Zhou, Shuai Zhao, and Wafik S. El-Deiry from Fox Chase Cancer Center and Brown University explore the potential of combining TAS102 (triflurid…

1
TCR CDR3s and Renalase-1 Linked to Increased Melanoma Survival 2:31

5d ago2:31

2:31

BUFFALO, NY- August 8, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on August 5, 2024, entitled, “Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival.”As mentioned in the Abstract of this study, overexpression of the secretory protein renalase-1 negati…

1
Dealing with Runaway Metastatic Disease 1:59

7d ago1:59

1:59

BUFFALO, NY - August 7, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on July 12, 2024, entitled, “How to deal with runaway metastatic disease?”In this new editorial, Justine Paris and Guilhem Bousquet from Université Paris Cité, Université Sorbonne Paris Nord, and APHP, Hôpital Avicenne, Oncologie médical, discussed how th…

1
INT-1B3 miR-193a-3p Mimic Boosts T Cell Immunity and Induces Tumor Cell Death 2:34

8d ago2:34

2:34

BUFFALO, NY- August 5, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on July 12, 2024, entitled, “INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogenic cell death.”In this study, resear…

1
Prognostic and Therapeutic Insights Into MIF, DDT, and CD74 in Melanoma 3:32

18d ago3:32

3:32

BUFFALO, NY- July 26, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on July 19, 2024, entitled, “Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma.”Macrophage Migration Inhibitory Factor (MIF) and its homolog D-dopachrome Tautomerase (DDT) have been implicated as drivers of tumor progression across a va…

1
Novel Triple-Drug Combination to Fight Pancreatic Cancer 8:10

19d ago8:10

8:10

In the ever-evolving quest for effective cancer treatments, researchers are continuously exploring innovative combinatorial approaches that exploit the vulnerabilities of malignant cells. In a new study, researchers Benigno C. Valdez, Apostolia M. Tsimberidou, Bin Yuan, Yago Nieto, Mehmet A. Baysal, Abhijit Chakraborty, Clark R. Andersen, and Borje…

1
Prevalence and Impact of the KIT M541L Variant in Patients with Mastocytosis 2:54

20d ago2:54

2:54

BUFFALO, NY- July 24, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on July 22, 2024, entitled, “Prevalence and impact of the KIT M541L variant in patients with mastocytosis.”Activating mutations in KIT, particularly D816V, have been associated with mastocytosis. Additionally, expression of heterozygous KIT M541L has been pr…

1
Oncotarget Welcomes New Editorial Board Members 1:40

22d ago1:40

1:40

BUFFALO, NY - July 22, 2024 – Oncotarget proudly welcomes new members to our esteemed Editorial Board, including our new Co-Editor-in-Chief, Dr. Wafik S. El-Deiry. Joining Dr. El-Deiry on Oncotarget’s Editorial Board are Dr. Trever Bivona, Dr. Phillip Buckhaults, Dr. Fred Bunz, Dr. Jonathan Chernoff, Dr. Stephen G. Chun, Dr. Nathan Dolloff, Dr. Pei…

1
Efficacy of Pembrolizumab with sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC 3:21

22d ago3:21

3:21

BUFFALO, NY- July 22, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on July 10, 2024, entitled, “Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.”Patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) after …

1
DDX41’s Unique Contribution to Myeloid Leukemogenesis 2:35

25d ago2:35

2:35

BUFFALO, NY- July 19, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on July 2, 2024, entitled, “DDX41 and its unique contribution to myeloid leukemogenesis.”In this new editorial, researcher Hirotaka Matsui from the National Cancer Center Hospital in Tokyo, Japan, and Kumamoto University discusses myeloid neoplasms. Until t…

1
Using Early On-treatment ctDNA Measurements as Response Assessment in mCRPC 2:34

27d ago2:34

2:34

BUFFALO, NY- July 17, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on July 2, 2024, entitled, “Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer.”In this new editorial, researchers S.H. Tolmeijer, E. Boerrigter, N.P. Van Erp, and Niven Mehr…

1
HER2-low and HER2-zero in Breast Cancer Between Prognosis, Prediction and Entity 2:41

28d ago2:41

2:41

BUFFALO, NY- July 16, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on June 20, 2024, entitled, “HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity.”In this new editorial, researchers Marcus Schmidt, Hans-Anton Lehr, and Katrin Almstedt from the University Medical Center of Johannes Gutenberg U…

1
Comparison of FDG-PET/CT and CT for Treatment Evaluation of Patients With Unresectable Mesothelioma 4:12

29d ago4:12

4:12

BUFFALO, NY- July 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.”Malignant pleural mesothelio…

1
AI for Improved PET/CT Attenuation Correction in Prostate Cancer Imaging 5:51

1M ago5:51

5:51

Positron Emission Tomography (PET) combined with Computed Tomography (CT) is a powerful imaging modality used in oncology for diagnosis, staging, and treatment monitoring. However, one limitation of PET/CT is the need for accurate attenuation correction (AC) to account for tissue density variations. Traditionally, low-dose CT scans are used for AC,…

1
Targeting ABC Transporters in PDAC – Past, Present, or Future? 3:00

1M ago3:00

3:00

BUFFALO, NY- July 10, 2024 – A new #editorial paper was #published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Targeting ABC transporters in PDAC – past, present, or future?”In this new editorial, Cecilia Bergonzini, Elisa Giovannetti and Erik H.J. Danen from Leiden University discuss targeting ABC transporters in pancreatic ductal carci…

1
Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers 3:25

1M ago3:25

3:25

BUFFALO, NY- July 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on July 2, 2024, entitled, “Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status.”Single-agent TAS1…

1
Editorial: Genomics Has More to Reveal 2:33

1M ago2:33

2:33

BUFFALO, NY- July 2, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Genomics has more to reveal.”In this new editorial, researchers Laurène Fenwarth and Nicolas Duployez from the University of Lille and CHU Lille discuss molecular and cytogenetic analyses that are now used to identify mutations and…

1
Starving Cancer Cells to Enhance DNA Damage and Immunotherapy Response 2:55

2M ago2:55

2:55

BUFFALO, NY- June 26, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Starving cancer cells to enhance DNA damage and immunotherapy response.”Prostate cancer (PCa) poses significant challenges in treatment, particularly when it progresses to a metastatic, castrate-resistant state. Conventional …

1
Leveraging Gold Nanostars for Precision Laser Interstitial Thermal Therapy 2:42

2M ago2:42

2:42

BUFFALO, NY- June 24, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 14, 2024, entitled, “Leveraging gold nanostars for precision laser interstitial thermal therapy.”In this new editorial, researchers Aden P. Haskell-Mendoza, Ethan S. Srinivasan, Tuan Vo-Dinh and Peter E. Fecci from Duke University discuss laser inters…

1
Impact of Dual Immunotherapies Before Surgery in HR+/HER2-negative Breast Cancer 8:47

2M ago8:47

8:47

Breast cancer immunotherapy has shown promise, but its clinical efficacy remains limited, especially for hormone receptor positive (HR+)/HER2-negative breast cancer. While immune checkpoint inhibitors combined with chemotherapy have benefitted some early-stage and metastatic triple-negative breast cancer patients, HR+/HER2-negative cases have seen …

1
Assessment of CEA, CA-125, and CA19-9 as Adjuncts in Non-small Cell Lung Cancer Management 3:24

2M ago3:24

3:24

BUFFALO, NY- June 19, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 13, 2024, entitled, “Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management.”Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. In this new study, r…

1
When Does a Melanoma Metastasize? Implications for Management 2:18

2M ago2:18

2:18

BUFFALO, NY- June 18, 2024 – A new #research perspective was #published in Oncotarget's Volume 15 on June 13, 2024, entitled, “When does a melanoma metastasize? Implications for management.”In this new perspective, researchers John F. Thompson and Gabrielle J. Williams from The University of Sydney, Royal Prince Alfred Hospital, and the University …

1
Impact Journals Sponsors 2024 Ride for Roswell 3:59

2M ago3:59

3:59

BUFFALO, NY- June 11, 2024 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 28 years to celebrate cancer survivors, pay trib…

1
Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations 8:07

2M ago8:07

8:07

In the relentless battle against non-small cell lung cancer (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations, the development of resistance has long been a formidable obstacle. Historically, first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) like gefitinib, erlotinib, afatinib, and dacomitinib have faced a signif…

1
Synergistic Cytotoxicity of HDAC and PARP Inhibitors and Decitabine in Pancreatic Cancer Cells 3:38

2M ago3:38

3:38

BUFFALO, NY- June 5, 2024 – A new research paper was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.”Histone deacetylase inhibitors (HDACi) can modulate the acetylation …

1
BTK Inhibitor-related Cardiotoxicity: Quest for Predictive Biomarkers, Improved Risk Stratification 2:29

2M ago2:29

2:29

BUFFALO, NY- June 4, 2024 – A new research perspective was published in Oncotarget's Volume 15 on June 3, 2024, entitled, “Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification.”In this new perspective, researchers Jai N. Patel, Jai Singh, and Nilanjan Ghosh from Atrium Healt…

1
Behind the Study: Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167 6:46

3M ago6:46

6:46

Dr. Benoit Chabot from Université de Sherbrooke in Quebec, CA, discusses a research paper he co-authored that was published by Oncotarget in Volume 15, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.”DOI - https://do…

1
The Importance of Integrated Therapies on Cancer: Silibinin, an Old and New Molecule 3:15

3M ago3:15

3:15

BUFFALO, NY- May 28, 2024 – A new review paper was published in Oncotarget's Volume 15 on May 23, 2024, entitled, “The importance of integrated therapies on cancer: Silibinin, an old and new molecule.”In this new review, researchers Elisa Roca, Giuseppe Colloca, Fiorella Lombardo, Andrea Bellieni, Alessandra Cucinella, Giorgio Madonia, Licia Martin…

1
Combating Doxorubicin-Resistant Acute Myeloid Leukemia 10:39

3M ago10:39

10:39

Upon diagnosing acute myeloid leukemia (AML), the initial step involves assessing a patient’s eligibility for intensive chemotherapy. The standard treatment protocol for newly diagnosed AML encompasses intensive chemotherapy to achieve complete remission, followed by post-remission therapy, which may include additional chemotherapy and/or stem cell…

1
GZ17-6.02 Kills Uveal Melanoma Cells 3:53

3M ago3:53

3:53

BUFFALO, NY- May 22, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 17, 2024, entitled, “GZ17-6.02 kills PDX isolates of uveal melanoma.”In this new study, researchers Laurence Booth, Jane L. Roberts, Ivan Spasojevic, Kaitlyn C. Baker, Andrew Poklepovic, Cameron West, John M. Kirkwood, and Paul Dent from Virginia Commonw…

1
Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167 via EMT and Antiviral Immune Response 3:19

3M ago3:19

3:19

BUFFALO, NY- May 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 16, 2024, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.”The diheteroarylamide-based compound 1C8 and the aminothiazole…

1
Expression of Cyclin D1 in Penile Cancer 3:36

3M ago3:36

3:36

BUFFALO, NY- May 15, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on May 14, 2024, entitled, “Cyclin D1 expression in penile cancer.”In this new study, researchers Wesliany Everton Duarte, Jaqueline Diniz Pinho, Syomara Pereira da Costa Melo, Denner Rodrigo Diniz Duarte, Juliana Martins da Guia Ribeiro do Carmo, André Salim…

1
Oncotarget at SSP 46th Annual Meeting 1:30

3M ago1:30

1:30

BUFFALO, NY- May 13, 2024 – BUFFALO, NY- May 13, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences, with a focus on all areas of cancer and aging research. Oncotarget is one of the most prominent journals published by Impact Journals.Impact Journals is proud to participate at the Society for Scholarly Publishing (SSP) 4…

1
SARS-CoV-2 Spike Protein Disrupts p53 Tumor Suppressor Pathway 9:24

3M ago9:24

9:24

The profound impact of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been felt across various domains, including the realm of cancer research and treatment. As scientists delve deeper into the intricate mechanisms of this viral pathogen, intriguing revelations have emerged regarding its potential influence on cellular processes pivotal…

1
Deep Learning-based Whole-body Prostate-specific Membrane Antigen PET/CT Attenuation Correction 3:42

3M ago3:42

3:42

BUFFALO, NY- May 8, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 7, 2024, entitled, “Deep learning-based whole-body PSMA PET/CT attenuation correction utilizing Pix-2-Pix GAN.”The sequential PET/CT studies oncology patients can undergo during their treatment follow-up course is limited by radiation dosage. In this new …

1
Transfected SARS-CoV-2 Spike DNA Suppresses Cancer Cell Response to Chemotherapy 4:01

3M ago4:01

4:01

BUFFALO, NY- May 6, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 3, 2024, entitled, “Transfected SARS-CoV-2 spike DNA for mammalian cell expression inhibits p53 activation of p21(WAF1), TRAIL Death Receptor DR5 and MDM2 proteins in cancer cells and increases cancer cell viability after chemotherapy exposure.”Severe acu…

1
Oncotarget Sponsors 19th International p53 Workshop in Italy 2:06

4M ago2:06

2:06

BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing #sponsor at the 19th International p53 Workshop, organized by the International Center for Genetic Engineering and Biotechnology (ICGEB), which takes place from May 13–16, 2024, in Trieste, Italy.“Groundbreaking research and cutting-edge advancements in the field of the most studied human g…

1
Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma 3:17

4M ago3:17

3:17

BUFFALO, NY- April 16, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on April 12, 2024, entitled, “Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface.”The B-cell receptor regulates B-cell proliferation and apoptosis. Aberrations in BCR signaling are associated wi…

1
Synergistic Effects of Drug Combinations Targeting AML Cells 5:48

4M ago5:48

5:48

Acute myeloid leukemia (AML) is a cancer characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. ABT199, also known as venetoclax, is a targeted therapy that inhibits the BCL-2 protein, which is often overexpressed in AML cells and contributes to the…

1
Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia 2:52

4M ago2:52

2:52

BUFFALO, NY- April 10, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.”Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the …

1
Identifying Biomarkers for Predicting Paclitaxel Response 5:48

5M ago5:48

5:48

Cancer therapy has come a long way from its one-size-fits-all beginning to the awakening era of personalized medicine. This change has been largely driven by the discovery of biomarkers. Biomarkers can help refine patient selection for specific therapies. A blend of causal and correlative approaches is needed to elucidate the full potential of biom…

1
Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer 3:15

5M ago3:15

3:15

BUFFALO, NY- March 27, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 19, 2024, entitled, “Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II–III breast cancer.”In this new study, researchers Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, …

1
ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells 3:21

5M ago3:21

3:21

BUFFALO, NY- March 25, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 14, 2024, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.”ABT199/venetoclax, an inhibitor of the pro-survival BCL-2 protein, has improved AML treatment. Its effica…

1
Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal® 3:18

5M ago3:18

3:18

BUFFALO, NY- March 20, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on March 14, 2024, entitled, “Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay.”In this new study, researchers Josette Northcott, Gabor Bartha, Jason Harris, Conan Li, Fabio C.P. Navarro, Rachel Marty Pyke…

1
“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny 1:55

5M ago1:55

1:55

BUFFALO, NY- March 19, 2024 – A new #research perspective was #published by Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center in Oncotarget's Volume 15 on March 15, 2024, entitled, “From osimertinib to preemptive combinations.”“Here, I suggest that while first-line osimertinib extends median progression-free surviva…

1
A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation 3:32

5M ago3:32

3:32

BUFFALO, NY- March 18, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on March 14, 2024, entitled, “G-quadruplex landscape and its regulation revealed by a new antibody capture method.”In this new study, researchers Subhamoy Datta, Manthan Patel, Chakkarai Sathyaseelan, Chandrama Ghosh, Akanksha Mudgal, Divyesh Patel, Thenmala…

1
Antitumor Effects of Sacituzumab Govitecan Plus Platinum-Based Chemotherapy 5:13

5M ago5:13

5:13

The relentless search for effective cancer therapies has led to numerous breakthroughs in drug discovery and development. Advancements have emerged in recent years through the promising avenue of combination therapy, where two or more drugs are used synergistically to enhance their collective therapeutic effect. This strategy has shown significant …

Podcasts Worth a Listen

Oncotarget Podcasts

Podcasts Worth a Listen

Quick Reference Guide